Mini-symposia offer in-depth knowledge into a specific area of delivery science and technology, featuring three invited speakers sharing their research on the topic.
Breakthrough Technologies in Drug Delivery Systems from Asia
This symposium is sponsored by the Japanese Society of Drug Delivery System (JSDDS) to highlight breakthrough technologies in the field of drug delivery systems, especially from Asia, where there are emerging papers in cutting-edge fields such as gene delivery and regenerative medicine. The program committee for this mini-symposium comes from JSDDS, since the choice of invited speakers should be fair and reasonable. This committee is now considering the criteria based on the citation of JCR from 2008 to 2012 with the help of Jaap van Harten. The details of this process will be explained in the mini-symposium at CRS 2013.
Kwangmeyung Kim, KIST, Korea
Hirofumi Takeuchi, Gifu Pharmaceutical University, Japan
Zhiyuan Zhong, Soochow University, China
Drug Combination Products
This mini-symposium will focus on therapeutics whose mechanism of action is based on surprising benefits achieved when taking two compounds and delivering them as a single product. This type of drug product will likely challenge the FDA’s current definition of a drug combination product, as the combined agents may each be novel and when used alone will not exhibit optimized therapeutic activity. This is exemplified by synthetic lethality strategies where combinations of two genetic alterations are required to achieve a desired effect, yet single genetic alterations have no measurable effect. Another example would include products that promote synergistic drug-drug interactions. When using such combinations, controlled released formulations must be considered to achieve temporal control and site-specific delivery of both active agents.
Charlie Boone, University of Toronto, Canada
Lawrence Mayer, Celator Pharmaceuticals Corporation, Canada
Liangfang Zhang, University of California, San Diego
Energy: Problems within the Industry that Controlled Delivery Can Solve
Worldwide energy consumption continues to rise, and technological solutions are needed to increase energy production. How can we, encapsulation and controlled release scientists, help find solutions to make energy production more efficient, more reliable, or more sustainable?
This mini-symposium is focused on controlled release technologies used in the energy field. Included are the use of high-temperature phase change materials for solar energy storage and methods for enhanced oil recovery (EOR) and spill cleanup. Presentation scope will range from the state of the current art to the unmet needs in these fields to stimulate the discussion between scientists and end users.
Anne Dalager Dyrli, RESMAN, Norway
Jo Darkwa, University of Nottingham Ningbo, China
James Oxley, Southwest Research Institute, U.S.A.
Hybrid Groups: Bridging the Gap Between Industry and Academia
Publically funded healthcare research programs within academia generate important discoveries; however, the therapeutic and commercial potential of these discoveries is difficult to assess. The discoveries are simply too early to be considered for further support by the private sector, and further research support from the public sector is difficult to obtain. In recognition of this “funding gap,” hybrid institutions—institutions that are not academic or industry based—are being formed to provide expertise and infrastructure to enable researchers to advance promising early-stage drug candidates to a point where further investments from the private sector are more realistic. In doing so, these groups derisk discoveries arising from academia and transform them into viable investment opportunities for the private sector. This session will highlight such hybrid organizations that have formed in three different countries.
Karimah Es Sabar, Center for Drug Research and Development, Canada
Patrick Griffin, Translational Research Institute, The Scripps Research Institute, U.S.A.
Bert Klebl, The Lead Discovery Center at Max Planck, Germany
Nanoparticles and Cancer
Nanoparticles—formed from polymers, lipids, and other materials—are rapidly becoming important tools in the treatment of cancer in humans. This mini-symposium presents recent progress in the design, manufacture, and use of nanoparticles for cancer. Several nanoparticle formulations have now been tested clinically, and a few are approved for use in humans. From this experience, it is possible to define some of the characteristics of nanoparticles that make them most effective for cancer therapy.
Michelle Bradbury, Memorial Sloan Kettering Cancer Center, U.S.A.
Jordan Green, Johns Hopkins University, U.S.A.
Yuanpei Li, University of California-Davis, U.S.A.